Literature DB >> 6549147

Problems in evaluating response of primary breast cancer to systemic therapy.

G Cocconi, B Di Blasio, G Alberti, G Bisagni, E Botti, G Peracchia.   

Abstract

The evaluation of the response of primary breast cancer to systemic therapy is difficult. Evaluable primary lesions may be assessed both by physical and by mammographic examination. In this study, response to therapy was evaluated after 4 cycles of CMF or CMF plus tamoxifen in 49 patients with locally advanced breast cancer entering a prospective randomized trial. In 35 patients response was evaluated by both physical examination and mammography. In some cases there was disagreement between physical examination and mammography in quantifying the magnitude of response. In 8 of 35 (22.9%), the overall response was overestimated by physical examination versus mammography, while in 3 of 35 (8.6%) the reverse was true. Taking into consideration different criteria in attributing the overall response, i.e. selecting physical examination only, mammography only, or the most favorable or the least favorable response between the two methods of assessment, the objective remission rates were 65.7%, 54.3%, 71.4% and 45.7%, respectively. The data suggest that both physical examination and mammography should be used in evaluating the response of primary breast cancer to a systemic treatment. Should these two methods yield contrasting results, the data obtained with each method should be reported. The best observed response may be employed in determining the overall response.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6549147     DOI: 10.1007/bf01806044

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

1.  Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland.

Authors:  J L Hayward; P P Carbone; J C Heuson; S Kumaoka; A Segaloff; R D Rubens
Journal:  Cancer       Date:  1977-03       Impact factor: 6.860

2.  Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland.

Authors:  J L Hayward; R D Rubens; P P Carbone; J C Heuson; S Kumaoka; A Segaloff
Journal:  Eur J Cancer       Date:  1978-11       Impact factor: 9.162

3.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

4.  Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer.

Authors:  M De Lena; R Zucali; G Viganotti; P Valagussa; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

5.  Treatment of advanced squamous cell carcinoma of the head and neck with cisplatin, bleomycin, and methotrexate (PBM).

Authors:  T J Ervin; R Weichselbaum; D Miller; M Meshad; M Posner; R Fabian
Journal:  Cancer Treat Rep       Date:  1981 Sep-Oct

6.  Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard.

Authors:  G P Canellos; S J Pocock; S G Taylor; M E Sears; D J Klaasen; P R Band
Journal:  Cancer       Date:  1976-11       Impact factor: 6.860

7.  Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.

Authors:  G Rosen; B Caparros; A G Huvos; C Kosloff; A Nirenberg; A Cacavio; R C Marcove; J M Lane; B Mehta; C Urban
Journal:  Cancer       Date:  1982-03-15       Impact factor: 6.860

8.  Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study.

Authors:  G Cocconi; V De Lisi; C Boni; P Mori; P Malacarne; D Amadori; E Giovanelli
Journal:  Cancer       Date:  1983-02-15       Impact factor: 6.860

  8 in total
  14 in total

1.  Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer.

Authors:  Filippo Montemurro; Laura Martincich; Giovanni De Rosa; Stefano Cirillo; Vincenzo Marra; Nicoletta Biglia; Marco Gatti; Piero Sismondi; Massimo Aglietta; Daniele Regge
Journal:  Eur Radiol       Date:  2005-01-27       Impact factor: 5.315

2.  Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer.

Authors:  Jason D Keune; Donna B Jeffe; Mario Schootman; Abigail Hoffman; William E Gillanders; Rebecca L Aft
Journal:  Am J Surg       Date:  2010-04       Impact factor: 2.565

Review 3.  In vivo 1H MRS in the assessment of the therapeutic response of breast cancer patients.

Authors:  Uma Sharma; Hyeon Man Baek; Min Ying Su; Naranamangalam R Jagannathan
Journal:  NMR Biomed       Date:  2011-01-28       Impact factor: 4.044

4.  Ultrasound-Guided Diffuse Optical Tomography for Predicting and Monitoring Neoadjuvant Chemotherapy of Breast Cancers: Recent Progress.

Authors:  Chen Xu; Hamed Vavadi; Alex Merkulov; Hai Li; Mohsen Erfanzadeh; Atahar Mostafa; Yanping Gong; Hassan Salehi; Susan Tannenbaum; Quing Zhu
Journal:  Ultrason Imaging       Date:  2015-04-16       Impact factor: 1.578

5.  Chemotherapeutic drug-specific alteration of microvascular blood flow in murine breast cancer as measured by diffuse correlation spectroscopy.

Authors:  Gabriel Ramirez; Ashley R Proctor; Ki Won Jung; Tong Tong Wu; Songfeng Han; Russell R Adams; Jingxuan Ren; Daniel K Byun; Kelley S Madden; Edward B Brown; Thomas H Foster; Parisa Farzam; Turgut Durduran; Regine Choe
Journal:  Biomed Opt Express       Date:  2016-08-24       Impact factor: 3.732

6.  Diffuse Optical Monitoring of the Neoadjuvant Breast Cancer Therapy.

Authors:  Regine Choe; Turgut Durduran
Journal:  IEEE J Sel Top Quantum Electron       Date:  2011-12-02       Impact factor: 4.544

7.  The effect of chemotherapy on the mammographic appearance of breast cancer and correlation with histopathology.

Authors:  Kunal A Mistry; Meenakshi H Thakur; Seema A Kembhavi
Journal:  Br J Radiol       Date:  2015-10-23       Impact factor: 3.039

Review 8.  The emerging role of photoacoustic imaging in clinical oncology.

Authors:  Li Lin; Lihong V Wang
Journal:  Nat Rev Clin Oncol       Date:  2022-03-23       Impact factor: 66.675

9.  Imaging in evaluation of response to neoadjuvant breast cancer treatment.

Authors:  L Ollivier; C Balu-Maestro; J Leclère
Journal:  Cancer Imaging       Date:  2005-05-24       Impact factor: 3.909

10.  Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer.

Authors:  M Bhattacharyya; D Ryan; R Carpenter; S Vinnicombe; C J Gallagher
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.